key: cord-0301391-sg6r3qim
authors: Du, Canwei; Guan, Xin; Yan, Jiusheng
title: Two-pore channel blockade by phosphoinositide kinase inhibitors YM201636 and PI-103 determined by a histidine residue near pore-entrance
date: 2022-02-12
journal: bioRxiv
DOI: 10.1101/2022.02.11.480111
sha: 0afae507235874b04e77095ab274765725040958
doc_id: 301391
cord_uid: sg6r3qim

Human two-pore channels (TPCs) are endolysosomal cation channels and play an important role in NAADP-evoked Ca2+ release and endomembrane dynamics. TPCs are activated by PI(3,5)P2, which is synthesized by PIKfyve. Here, we found that YM201636, a widely used PIKfyve inhibitor, potently inhibits PI(3,5)P2-induced human TPC2 channel Na+ currents in a dose-dependent manner with an IC50 of 0.16 μM. YM201636 also effectively inhibits the currents of a constitutively open TPC2 mutant channel, whereas it exerts no effect when applied in the channel’s closed state. A YM201636 analog, PI-103, an inhibitor of PI3K and mTOR, also inhibits human TPC2 with an IC50 of 0.64 μM. Substitution of the pore-constriction residues Leu690, Leu694 and Tyr312 by Ala reduced the effectiveness of YM201636 and PI-103 in channel inhibition. Interestingly, a His699 residue located near the cytosolic pore entrance is a key determinant for the TPC2 channels’ sensitivity to YM201636 and PI-103, whose substitution with a Phe in the human TPC1 largely accounts for the channel’s loss of inhibition by YM201636. Molecular dynamic simulation and docking analysis of YM201636’s binding to TPC2 indicated that His699 can interact with the inhibitor and facilitate the channel-blockade at the cytosolic end of the pore. We conclude that YM201636 and PI-103 directly block the TPC2’s open-state channel pore at the cytosolic entrance where the His699 is a key determinant for the blockers’ access to the pore. These findings identify two new potent TPC2 channel blockers, reveal a channel pore entrance blockade mechanism, and provide a new protein target in interpreting the pharmacological effects of these two widely used phosphoinositide kinase inhibitors.

Two-pore channels (TPCs) are mainly found in acidic organelles of endolysosomes in animals and also vacuoles in plants. Humans and mice have two functional TPC isoforms: TPC1, which is broadly expressed in different stages of endosomes and lysosomes, and TPC2, which is expressed mainly in latestage endosomes and lysosomes 1, 2 . TPCs are homodimeric cation channels whose each subunit contains two transmembrane domains of the basic structural unit (six transmembrane segments and a pore loop) of a voltage-gated ion channel. They are potently activated by phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2) [3] [4] [5] [6] , inhibited by ATP via mTORC1 7 , and slightly blockaded by cytoplasmic and luminal Mg 2+ 5 . Human TPC1 is voltage-gated and regulated by cytoplasmic and luminal Ca 2+ 8 , whereas human TPC2 is not sensitive to voltage or Ca 2+ 5 . The recently reported cryo-electron microscopic (Cryo-EM) structures of mouse TPC1 9 and human TPC2 10 have provided a structural basis for understanding TPC function.

The endolysosomal TPCs regulate the function of the endolysosomal system, including endomembrane dynamics and Ca 2+ homeostasis of the acidic stores 3, 11 . Accumulating evidence supports that TPCs are critical to NAADP-evoked Ca 2+ release from acidic stores 1, [12] [13] [14] [15] [16] [17] [18] . TPCs are involved in many cellular processes, including autophagy 19 , migration and proliferation of cancer cells 20, 21 , muscle cell differentiation 22 and contraction 16 , and fertilization 23 , and they are implicated in pigmentation 24-26 , Parkinson's disease 27 , and fatty liver disease 28, 29 . TPCs are also important to infection mechanisms of viruses, such as Ebola 30 , MERS 31 , and SARS-COV-2 32 .

Potent and/or selective modulators are important pharmacological tools in understanding an ion channel molecular mechanisms and physiological and pathological function. Currently, almost no potent and/or selective antagonists of TPCs have been identified. It is unknown if Ned-19 (trans- Ned 19) , an NAADP signaling antagonist 33 , can directly target TPCs 34 despite its ability to form complex with plant TPC1 35 . Naringenin, a modulator of multiple ion channels, can inhibit TPCs when applied at high concentrations (an IC50 of ~200 µM) 36 , likely via the blockade of the channel pore. Tetrandrine, a voltagegated Ca 2+ (CaV) channel blocker, was reported to improve Ebola virus entry into host cell via potent inhibition of TPCs 30 . However, a direct action of tetrandrine on TPCs remains to be proven 34 . Some other CaV and NaV channel antagonists, such as nifedipine and lidocaine, were also found to inhibit NAADPevoked Ca 2+ elevation in cells and have been proposed to act as antagonists of TPCs 37 . But, electrophysiological evidence for TPC inhibition by CaV and NaV antagonists is lacking. Therefore, potent and/or selective antagonists of TPCs have yet to be identified or established.

We considered two candidates. YM201636 is a potent and selective inhibitor (an IC50 of ~30 nM) of PIKfyve, the principal phosphoinositide kinase that produces PI (3, 5) P2 via PtdIns3Pphosphorylation 38, 39 .

Given that PI(3,5)P2 is a key component and regulator of the endolysosomal system, YM201636 is widely used in research studies to disrupt endomembrane transport, e.g., to prevent infection by Zaire ebolavirus and SARS-COV-2 32, 40 or to inhibit retroviral release from infected cells 41 . Similarly, PI-103 is a potent multi-target inhibitor of class I phosphatidylinositol 3-kinase (PI3K), mammalian target of rapamycin complex (mTOR), and DNA-dependent protein kinase (DNA-PK) 42 . PI-103 has nearly the same chemical structure as YM201636 but without YM201636's 6-amino-nicotinamide group. In this study, we identified YM201636 and PI-103 as potent inhibitors of human TPC2 channels, and we further investigated and identified the mechanisms underlying their inhibitory effects on TPCs.

channels TPC channel activities are dually modulated by two endogenous signaling molecules: NAADP and PI (3, 5) P2. It is unclear whether TPC2-mediated NAADP and PI(3,5)P2 signaling processes can mutually affect each other. Therefore, we tested whether suppression of PI (3, 5) P2 production by application of a PIKfyve inhibitor, YM201636, affects NAADP-evoked Ca 2+ release. We observed that direct microinjection of YM201636 greatly reduced NAADP-evoked Ca 2+ elevation in HEK293 cells (Fig. 1A) . However, HEK293 cells' response to NAADP was largely unaffected upon microinjection of apilimod, another potent PIKfyve inhibitor (Fig. 1A) . Taking advantage of the plasma membrane-targeted TPC2 L11A/L12A mutant (TPC2 PM ) channels 9,10 , we performed an inside-out patch-clamp recording of the TPC2 PM currents to determine whether YM201636 directly acts on these channels. We observed that YM201636 application from the cytosolic side at sub-micromolar concentrations directly inhibited PI(3,5)P2-induced human TPC2 channel Na + currents (Fig. 1B) . YM201636 potently inhibited TPC2 channels in an antagonist concentration-dependent manner at a low IC50 of 0.16 μM (Fig. 1C) . YM201636's inhibition of the human TPC2 channel was voltage-independent, as shown by the similar levels of inhibition at both negative and positive voltages (Fig. 1D) .

For comparison, we also tested the effect of some previously reported TPC inhibitors. We first performed inside-out patch-clamp recording of PI(3,5)P2-activated TPC currents and applied the inhibitors from the cytosolic side. Unexpectedly, tetrandrine at even 10 µM could only slightly inhibit the PI(3,5)P2induced TPC2 currents by ~10% (Fig. 1E) , which is in stark contrast to the previously reported large inhibition of lysosomal TPC2 currents by 0.5 µM tetrandrine applied from the cytosolic side 30 . Similarly, Ned-19 at 10 µM only marginally inhibited TPC2 currents (Fig. 1E) . The CaV channel blocker nifedipine at 10 µM showed no effect on TPC2 currents (Fig. 1E ).

Next, we performed whole-cell recording and applied the inhibitors from the extracellular side, which is analogous to the luminal side of the lysosome. In this experiment, we activated the TPC currents by perfusion of the activator TPC2-A-N1 on the extracellular side. Although YM201636 at 1 µM still caused ~70% inhibition of the currents when applied from the extracellular side (Fig. 1F) , it was less potent applied from the extracellular side than when it was applied on the cytosolic side, suggesting possible action of this inhibitor from the cytosolic side. Its action from the extracellular side presumably resulted from its high lipophilicity property, which allows it to cross the membrane. Interestingly, both tetrandrine and Ned-19 inhibited TPC2 much more effectively when applied from the extracellular side, as their application at 10 µM reduced TPC2 curretnts by ~60% and 50%, respectively (Fig. 1F) . However, both tetrandrine and Ned-19, even at higher levels such as 10 µM were less effective than YM201636 at 1 µM. Nifedipine at 10 µM had no effect on TPC2 currents when applied on the extracellular side (Fig. 1F) . Therefore, we concluded that YM201636 is thus far the most potent inhibitor of human TPC2 available. In addition, given the complexity of the NAADP signaling process, which is not well understood yet, our results showed that a direct analysis of the channel activity by electrophysiology is needed to determine whether these observed effects on NAADP signaling were actually caused by the inhibitors' action on TPCs.

When applied from the cytosolic side, PI(3,5)P2 activated human TPC2 channels with an observed activation rate, τon, of ~10 s, and the effect could be washed off within 1-2 minutes with a deactivation rate of a τoff of ~20 s ( Fig. 2A) . We found YM201636 inhibited the human TPC2 channel quickly with a τon of ~2 s when the channels were pre-activated by PI(3,5)P2 (Fig. 2B) . The wash-off of YM201636 in the presence of PI(3,5)P2, i.e., in the open state, was slow at a τoff rate of ~60 s (Fig. 2B) . To determine the state dependence of YM201636 binding to the human TPC2 channel, we applied YM201636 when the channels were in the closed state, i.e., in the absence of PI(3,5)P2 for 2 min, followed by the activation of the channels by PI (3, 5) P2 in the absence of YM201636 (Fig. 2C) . We found that the time courses of TPC2 currents activated by PI (3, 5) P2 were similar in the absence and presence of the pre-application of YM21636 ( Fig. 2A , C, and D), indicating that YM201636 cannot bind to TPC2 for channel inhibition in the closed state. To evaluate the wash-off rate of YM201636 in the channel's closed state after the channels were inhibited by YM201636, we washed the excised patches with the bath solution alone (no PI(3,5)P2 and YM201636) for different time lengths and then applied PI (3, 5) P2 to check the residual effect of YM201636 on channel activation ( Fig. 2E-G) . We found that the residual effect of YM201636 on PI(3,5)P2-induced channel activation after perfusion with the bath solution alone was washing time-dependent. The residual inhibitory effects were estimated to be 58%, 33%, and 19% after a 40-s, 80-s and 120-s wash, respectively (Fig. 2H) , a time course that was similar to that observed for the inhibition left when YM201636 was washed off in the presence of PI(3,5)P2 ( Fig. 2B) . Therefore, YM201636 can only bind to and inhibit the channels when the channels are activated, whereas its dissociation is largely independent of the presence or absence of PI(3,5)P2 or the channel's activation status.

To determine whether the inhibition of TPC2 by YM201636 is specific to any ligand or activation pathway, we performed Ala-substitution mutations in the T308, Y312, L690, and L694 residues, which have been predicted from human TPC2 structures to form a bundlecrossing activation gate on the cytosolic side of the channel pore 10 . We were unable to obtain functional channels from the single mutation of L690A or L694A. However, the double mutant channel L690A/L694A produced Na + currents in the absence of any agonist, and application of PI(3,5)P2 did not increase the currents (Fig. 2I) , indicating that the channels are already constitutively fully open. This result provides functional evidence that these two residues are indeed involved in the formation of the activation gate. The T308A and Y312A mutant channels remained closed in the absence of an agonist and sensitive to PI(3,5)P2 for channel activation, suggesting that these two residues are less important in activation pore-gate formation. With the L690A/L694A mutant channel in the absence of an agonist, we observed that YM201636 could still reduce the channel's constitutively open currents in a concentration-dependent manner, with an IC50 of 0.54 μM ( Fig. 2J and K) . This result clearly indicates that YM201636's inhibition of the human TPC2 channel is independent of activation by any ligand. This inhibitory property of YM201636 agrees with a channel pore blocker. The more than 3-fold increase of YM201636's IC50 by the L690A/L694A double mutation also suggests a role of the pore structure in TPC2 inhibition by this inhibitor. Therefore, we consider YM201636 as a TPC2 open-channel pore blocker.

To identify the YM201636 binding sites along the channel pore, we performed an Ala scanning analysis among the channel pore residues (Fig. 3A) . Given its large size, the YM201636 molecule may interact with residues inside the pore and also those near the pore entrance. Therefore, we also examined the mutational effect of His699 residue, which is located immediately at the pore entrance on the cytosolic side (Fig. 3A) .

Compared to the L690A/L694A double mutation, the Ala-substitution of residues inside the channel pore by mutations N305A, T308A, S682A, V686A, and N687A showed little or less effect on TPC2 inhibition by 1 µM YM201636 (Fig. 3B) . Major reductions in sensitivity to YM201636 were observed with mutations of the Y312 and H699 residues ( Fig. 3B-F) , which are located immediately below the L690/L694 pore-gate and near the cytosolic side of the pore entrance, respectively. The Y312A mutation significantly increased the IC50 for TPC2 inhibition by YM2.1636, by more than 4-fold (IC50 = 0.67 µM) ( Fig. 3C and F) . The H699A mutation drastically reduced the channel's sensitivity to YM201636, as indicated by a more than 20fold increase in the IC50 (IC50 = 4.33 µM) compared to that of the wild-type channel ( Fig. 3D and F) . The double mutation Y312A/H699A resulted in a much greater loss of the channel's sensitivity to YM201636, with an IC50 beyond the highest tested concentration (21 µM) ( Fig. 3E and F) ; i.e., the mutation resulted increased IC50 more than 100-fold compared to that of the wild-type channel. These results indicate that the cytosolic-side pore-gate formation of L690, L694, and Y312 residues, together with the H699 residue located immediately outside of the pore, determines YM201636's inhibitory effect on TPC2, likely by forming the inhibitor's binding sites.

To further analyze the impact of the mutations of H699 on TPC2's sensitivity to YM201636, we generated more mutations at this site. Similar to the effects of the H699A mutation, the H699F and H699N mutations greatly reduced inhibition of the channel by YM201636 with estimated IC50 values of ~2.2 and ~2.68 µM, respectively (Fig. 4A) . The H699Q and H699K mutations also reduced TPC2's sensitivity to YM201636 but to a much lesser extent (IC50s of ~0.7 µM and ~0.6 µM, respectively) than H699A, H699F, and H699N mutations did (Fig. 4A) . This finding suggests that substitution of histidine by a larger polar (Gln as compared to Asn) or positively charged residue at this position helps alleviate the loss in the channel's sensitivity to YM201636.

Interestingly, the TPC1 channel harbors a Phe (F692) at the equivalent TPC2-H699 position and displayed greatly reduced sensitivity to YM201636 (IC50 >20 µM) than that displayed by TPC2 ( Fig. 4B and C). Upon substitution with a histidine at this position by the F692H mutation, the TPC1 channel's sensitivity to YM201636 was greatly enhanced with a resulting IC50 of ~2.3 µM ( Fig. 4B and C) . Therefore, H699 is a key determinant for TPC2 channel's inhibition by YM201636, whose substitution with a Phe in the TPC1 channel partially accounts for the vastly decreased sensitivity to YM201636.

PI-103, a known PI3K and mTOR inhibitor, has nearly the same chemical structure as YM201636 but without a 6-amino-nicotinamide group (Fig. 5A) . We observed that PI-103 also directly inhibited the PI(3,5)P2-induced TPC2 channel Na + current (Fig. 5B) in a concentration-dependent manner with an IC50 of 0.64 μM (Fig. 5E) , which is 4-fold higher than that of YM201636, suggesting that the 6-amino-nicotinamide group has a role in enhancing the potency of YM201636's TPC2 blockade effect. Similar to that observed with YM201636, the Y312A mutation in TPC2 also resulted in reduced inhibition of the channel by PI-103 with an elevated IC50 of 13.9 µM (Fig. 5C and E) . The H699A mutation largely abolished the channel's blockade by PI-103 ( Fig. 5D and E) . Therefore, PI-103 acts similarly to YM201636 by functioning as a potent TPC2 channel blocker.

We initially performed a virtual molecular docking analysis via the AutoDock Vina program 43 molecules were docked at the bundle-crossing pore-gate region flanked by the Y312, R316, L690, L694, and E695 residues from the two identical subunits (Fig. 6A) . No preference in the orientation of the YM201636 molecule was observed, as the 6-amino-nicotinamide group pointed in and out of the pore in about equally often. PI-103 was similarly docked at a similar region, at which the top 30 poses had an average affinity of -10.11 kcal/mol, which was slightly lower in affinity than that of YM201636 and consistent with the increased IC50 of PI-103 compared to that of YM201636. However, the interactions of YM201636 and PI-103 with H699 were very limited or absent in their top 30 energetically favorable poses as the inhibitors were well-docked inside the pore whereas H699 is located outside of the pore.

Given the importance of the H699 residue in TPCs' sensitivity to the inhibitors, we hypothesized that H699 potentiates the channel blockade by interactions with the inhibitors around the pore entrance, allowing the inhibitor to block ion conductance directly at the pore entrance and/or alternatively the H699 to serve as initial docking sites to guide and facilitate the inhibitors to move toward the more favorable binding sites inside the pore. To identify the inhibitors' binding poses around the pore entrance, we limited the docking grid space to the pore entrance region. With this docking space restriction, we were able to observe YM201636's bindings at the pore entrance region below the pore-gate with a suboptimal average affinity of -9.27 kcal/mol for the top 30 poses (Fig. 6B) . Among most (n = 26) of these 30 top poses, the imidazole ring of H699 interacted closely (within 4 Å excluding hydrogen atoms) with YM201636. The interactions with H699 appeared flexible, involving nearly all the different parts of YM201636 in different poses, suggesting that these interactions are likely dynamic. Similarly, PI-103 was also observed to bind at the pore entrance, although the averaged affinity for the top 30 poses was reduced to -8.19 kcal/mol. We selected 4 representative poses of YM201636 in complex with TPC2 (Fig. 6C) for further analysis by molecular dynamic simulations for 100 ns. For the first three simulations, the initial poses appeared to be only relative stable for only a short period, e.g., ~ 20 ns, and then became more mobile and adopted new binding modes different from the initial one. However, no full escape from the pore entrance was observed during these 100 ns simulations. For the fourth simulation, the YM201636's interactions with the channel pore became enhanced in that the inhibitor moved slightly inward the pore and kept the pore entrance blocked during the 100 ns simulation as indicated by some interactions with the pore gate region residues L694 and A309 (Fig. 6C) . With the PyContact program 44 , we performed a systematic analysis of the interactions between YM201636 and protein residues in the four 100ns simulation trajectories and found that YM201636 remained strongly interacting with H699 most time (Fig. 6D) , including H-bond interaction (20% in average). According to the mean contact score and total contact time, YM201636 interacted predominantly with R316, H699, and E695, secondarily with L698 and M320, and marginally with Y312, S313 and N696 (Fig. 6D) . The results of molecular dynamic simulations on YM201636's bindings at and near the pore entrance indicate that the inhibitor dynamically interacts with the residues around the pore entrance and can move inside the pore for more sustained channel blockade. Similar to H699, we expect that R316 and E695 also play an important role in TPC2 inhibition by YM201636. The equivalent residues of R316 and E695 in X. tropicalis TPC3 were found to be important for the channel gating via electrostatic interactions and their mutations could result in non-functional channels 45 . Because both R316A and E695A mutations in human TPC2 produced non-functional channels, we pursued no further mutational analysis on them.

In this study, we identified YM201636 and its analog PI-103 to be potent human TPC2 channel blockers with IC50 values at a submicromolar range. YM201636 and PI-103 act similarly on TPC2 as their inhibitory effects on the channels are similarly affected by pore mutations. Importantly, as pore blockers, YM201636 and PI-103 can block the channels in an agonist-independent manner as YM201636 inhibited NAADP-evoked Ca 2+ elevation, PI(3,5)P2-activated TPC2 currents, and mutation-induced constitutively open TPC2 channels. Furthermore, YM201636 and PI-103 are TPC2 selective, as they are much less effective on TPC1 largely because of the His ↔ Phe switch near the cytosolic-side pore entrance (H699 on TPC2 vs. F692 on TPC1).

Given the channels' intracellular localization and difficulty in accessibility for the direct functional analysis of TPCs, some reported TPC inhibitors have been identified via indirect methods, e.g., Ca 2+ imaging of NAADP-evoked Ca 2+ elevationa cellular process that is not well understood and involves proteins more than TPCs. Therefore, it has remained to be scrutinized whether these drugs can inhibit TPC activity directly and effectively. Direct patch-clamp recording of enlarged endolysosomes is doable but technically challenging and not efficient. With the use of mutations, both TPC2 and TPC1 channels can be targeted to the plasma membrane 4,10 , which allows inside-out or whole-cell patch-clamp recording of TPCs to be done as with plasma membrane ion channels. In this study, we took advantage of the plasma membrane-targeted TPC mutant channels to obtain large and reliable recordings of the TPC currents and test putative TPC inhibitors for their effects on TPC2. Previously, it has been unclear whether the NAADP signaling antagonist Ned-19 can directly target TPCs 34 . We found that Ned-19 can inhibit TPC2 much more effectively from the extracellular side than from the cytosolic side, which is consistent with the more extracellular side location of its binding sites in the transmembrane domain of the plant TPC1 channel structure 35 . Although 10 µM Ned-19 can produce ~50% inhibition of TPC2 currents when applied from extracellular side, its action on TPC2 on lysosomes might require treatment of the cells with much higher concentrations because of the need of crossing both plasma and lysosome membranes to act on the luminal side of the lysosomes. Unexpectedly, tetrandrine, a reportedly potent TPC inhibitor, was largely ineffective when applied from the cytosolic side. However, it did inhibit TPC2 when applied from the extracellular side, but the required 10 µM concentration for an effective 60% inhibition is 20 times higher than previously reported (0.5 µM for ~60% inhibition of lysosomal TPC2 currents) and 200 times higher than the IC50 of ~55 nM for reduction of ebolavirus infection 30 . Furthermore, we found no support for the notion 37 that CaV antagonists in general, e.g., nifedipine, inhibit TPC2, as supported by our tests from both the cytosolic and extracellular sides. Our results demonstrate the necessity of a close examination of the putative TPC modulators, particularly those obtained from Ca 2+ -imaging analysis of NAADP-induced Ca 2+ elevation. The submicromolar IC50 values of YM201636 and PI-103, 0.16 µM and 0.6 µM, respectively, are much lower than those of Ned-19 or tetrandrine whose IC50 appeared to be close to 10 µM. Therefore, we considered YM201636 and PI-103 the most potent TPC2-selective antagonists available thus far.

We explored the mechanism of TPC2 inhibition by YM201636 and PI-103. First, we found YM201636 acts only when the channel is in an open state, i.e., pretreatment in the closed state has no effect.

However, its inhibitory effect is independent of the mechanisms of channel activation, consistent with the property of an open-channel pore blocker. Our mutational analyses showed the importance of the L690, L694, Y312, and H699 residues located at or near the cytosolic end of the channel pore on TPC2 inhibition by YM201636 and PI-103. The role of Y312 can be easily understood as it sits at the very cytosolic end of the channel pore and its side-chain forms the port to the channel pore. Similarly, the L690A/L694A double mutation, which caused the channel to constitutively open, alters the channel pore structure and thus affects the inhibitors' potency. However, structural perturbation of the H699 residue, which sits immediately outside of the pore, produced the largest impact on the TPC inhibition by YM201636 and PI-103. Its substitution with a Phe in human TPC1 also largely accounts for the greatly reduced sensitivity to the inhibitor. The role of H699 in TPC2 inhibition by YM201636 appears to be indispensable as mutations to other amino acids, regardless of size, polarity, or charge, all resulted in a loss of the channel's sensitivity to the inhibitor to some extent. The histidine residue plays a unique role in protein structure and function. Its imidazole side chain gives rise to its unique aromaticity and acid/base properties at a physiologic pH. YM201636 and PI-103 are chemicals of multiple rings with both aromatic and some polar properties. H699 could interact with YM201636 and PI-103 via both Van der Waals and hydrogen bond interactions including the π-π stacking, cation-π (if histidine is protonated), and hydrogen-π interactions 46 . Our molecular dynamic simulation analysis suggests that H699 can interact with YM201636 and PI-103 and contribute to the inhibitors' initial docking around the pore entrance. Overall, our data favor the possibility that YM201636 binding and blockade mainly occur at the cytosolic end of the pore as mutations deep in the pore had much less effect, and the H699 residue, which is immediately outside the pore, plays a key role in inhibition by interactions with the inhibitors around the pore entrance, allowing the inhibitor to block ion conductance directly at the pore entrance and/or alternatively serve as initial docking sites to facilitate the inhibitors to bind inside the pore. The slower process of YM201636's wash-off than its wash-on agrees with the notion that the inhibitor initially binds and blocks the channel at or near the pore entrance and then moves more inside the pore for more sustained channel blockade.

Both YM201636 and PI-103 have been widely used in research to target other proteins. Our studies thus identify a new important protein target of these two drugs. This also raises caution in interpretation of the potential mechanisms underlying the pharmacological effects of these two drugs, as the blockade of TPC2 could result in a broad range of cellular, physiological, and pathological effects as well. For example, PI-103 has some anti-tumor activity 47, 48 , and TPC2 is also considered to be implicated in cancer 20 .

YM201636 has anti-viral activity 32, 40 , and TPC2 also matters for virus entry 30, 32 . YM201636 is mainly used in research to target PIKfyve and block PI(3,5)P2 production. Although TPC2 is an effector of PI(3,5)P2 signaling, it can also be activated by other mechanisms, e.g., by NAADP via Lsm12 for TPC-mediated Ca 2+ mobilization 18 . Therefore, direct blockade of TPC2 by YM201636 can have a more profound effect than that caused by a reduction in PI(3,5)P2 synthesis via inhibition of PIKfyve activity. YM201636 and its derivative-based therapeutics could be an effective strategy to simultaneously target two virus entry-related proteins, PIKfyve and TPC2.

Given their broad physiological and pathological roles, TPCs are emerging as important therapeutic targets for many diseases including COVID-19. Currently, there is an unmet need to develop specific and potent antagonists targeting TPCs. Our identification of YM201636 and PI-103 as potent TPC2-selective (over TPC1) blockers and revelation of the underlying mechanism provide effective pharmacological tools to inhibit TPC2 currents and offers new templates for rational design of specific and potent inhibitors of TPC2.

HEK293 cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum, 1% penicillin, and streptomycin in a 5% CO2 incubator. Similar to our recent report 18 

Ca 2+ imaging analysis of NAADP-evoked Ca 2+ elevation was performed as we recently described 18 52 with the WYF parameter for cation-pi interactions 53 . The system was energy-minimized and then equilibrated in 6 steps using default input scripts for Gromacs generated by the CHARMM-GUI webserver.

After the equilibration, the systems were simulated for 200 ns with a 2 fs time step. The Nose-Hoover thermostat and a Parrinello-Rahman semi-isotropic pressure control were used to keep the temperature at 303.15 K and the pressure at 1 bar, respectively. A 12-Å cut-off was used to calculate the short-range electrostatic interactions, and the Particle Mesh Ewald summation method was employed to account for the long-range electrostatic interactions.

The data were processed and plotted with Igor Pro (v5), GraphPad Prism (v9), or OriginLab (v2015 or 2017). All statistical values are performed as means ± standard errors of the mean of n repeats of the experiments. Unpaired Student's t-test (two-tailed) was used to calculate p values. Unless indicated, all measurements or repeats were taken with distinct samples or cells. is shown in green and yellow, respectively, for the poses with their 6-amino-nicotinamide group pointed in and out of the pore. (C) The bottom views of the four representative poses (upper panels) and the side-views of the superimposed YM201636's conformations (50 frames; 2 ns/frame) during the 100 ns simulation (bottom). For clarity in A, B, and C (bottom panels), only a representative protein structure from a single frame is shown. (D) Plots of the mean contact scores and total contact times for residues interacting with YM201636. The data were obtained by analyses of their interactions in the trajectories of the four 100 ns molecular dynamic simulations with the Pycontact program. The scores and time were combined from the two identical residues of the two homodimeric subunits.

NAADP mobilizes calcium from acidic organelles through two-pore channels

The two-pore channel TPCN2 mediates NAADP-dependent Ca(2+)-release from lysosomal stores

TPC proteins are phosphoinositide-activated sodium-selective ion channels in endosomes and lysosomes

Tuning the ion selectivity of two-pore channels

Convergent regulation of the lysosomal twopore channel-2 by Mg(2)(+), NAADP, PI(3,5)P(2) and multiple protein kinases

The phosphoinositide PI(3,5)P(2) mediates activation of mammalian but not plant TPC proteins: functional expression of endolysosomal channels in yeast and plant cells

mTOR regulates lysosomal ATP-sensitive two-pore Na(+) channels to adapt to metabolic state

The human two-pore channel 1 is modulated by cytosolic and luminal calcium

Structural insights into the voltage and phospholipid activation of the mammalian TPC1 channel

Structural mechanisms of phospholipid activation of the human TPC2 channel

Purified TPC isoforms form NAADP receptors with distinct roles for Ca(2+) signaling and endolysosomal trafficking

Essential requirement for two-pore channel 1 in NAADP-mediated calcium signaling

An NAADP-gated two-pore channel targeted to the plasma membrane uncouples triggering from amplifying Ca2+ signals

Transient receptor potential mucolipin 1 (TRPML1) and two-pore channels are functionally independent organellar ion channels

Nicotinic acid adenine dinucleotide phosphate (NAADP) regulates autophagy in cultured astrocytes

TPC2 proteins mediate nicotinic acid adenine dinucleotide phosphate (NAADP)-and agonist-evoked contractions of smooth muscle

Expression of Ca(2)(+)-permeable two-pore channels rescues NAADP signalling in TPC-deficient cells

Lsm12 is an NAADP receptor and a two-pore channel regulatory protein required for calcium mobilization from acidic organelles

Endolysosomal two-pore channels regulate autophagy in cardiomyocytes

Two-Pore Channel Function Is Crucial for the Migration of Invasive Cancer Cells

Gene editing and synthetically accessible inhibitors reveal role for TPC2 in HCC cell proliferation and tumor growth

Role of Two-Pore Channels in Embryonic Development and Cellular Differentiation

NAADP and the two-pore channel protein 1 participate in the acrosome reaction in mammalian spermatozoa

The Two-pore channel (TPC) interactome unmasks isoform-specific roles for TPCs in endolysosomal morphology and cell pigmentation

TPC2 polymorphisms associated with a hair pigmentation phenotype in humans result in gain of channel function by independent mechanisms

TPC2 controls pigmentation by regulating melanosome pH and size

Two-Pore Channels and Parkinson's Disease: Where's the Link?

Pore Channels: Lessons from Mutant Mouse Models

Function and dysfunction of two-pore channels

Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment

NAADP-dependent Ca(2+) signaling regulates Middle East respiratory syndrome-coronavirus pseudovirus translocation through the endolysosomal system

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Identification of a chemical probe for NAADP by virtual screening

Targeting Two-Pore Channels: Current Progress and Future Challenges

Structure, inhibition and regulation of two-pore channel TPC1 from Arabidopsis thaliana

Naringenin Impairs Two-Pore Channel 2 Activity And Inhibits VEGF-Induced Angiogenesis

Two-pore channels provide insight into the evolution of voltage-gated Ca2+ and Na+ channels

Core protein machinery for mammalian phosphatidylinositol 3,5-bisphosphate synthesis and turnover that regulates the progression of endosomal transport. Novel Sac phosphatase joins the ArPIKfyve-PIKfyve complex

Homeostasis from a Structural-Biochemical Analysis of the PIKfyve Lipid Kinase Complex

Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2

Functional dissociation between PIKfyve-synthesized PtdIns5P and PtdIns(3,5)P2 by means of the PIKfyve inhibitor YM201636

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

PyContact: Rapid, Customizable, and Visual Analysis of Noncovalent Interactions in MD Simulations

Phosphoinositides modulate the voltage dependence of two-pore channel

The multiple roles of histidine in protein interactions

PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways

Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer

A kinematic view of loop closure

CHARMM-GUI Membrane Builder toward realistic biological membrane simulations

GROMACS: fast, flexible, and free

Simulations Using the CHARMM36 Additive Force Field

Cation-pi interactions between methylated ammonium groups and tryptophan in the CHARMM36 additive force field

We thank Ashli R. Villarreal and Sarah Bronson at Research Medical Library of MD Anderson Cancer Center for editing this article. This work was supported by National Institutes of Health grants GM130814 (J.Y.).

C.D. and J.Y. designed experiments, analyzed data, and wrote the manuscript. C.D. performed all electrophysiological experiments. X.G. performed calcium imaging experiment.

The authors declare no competing interests.